Italia markets close in 8 hours 9 minutes

Bristol-Myers Squibb Company (0R1F.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
72,70+0,20 (+0,28%)
Al 06:03PM GMT. Mercato aperto.

Bristol-Myers Squibb Company

430 East 29th Street
14th Floor
New York, NY 10016
United States
212 546 4000

Impiegati a tempo pieno32.200

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Giovanni Caforio M.D.Chairman & CEO5,82MN/D1965
Mr. David V. ElkinsExec. VP & CFO3,18M1,3M1968
Ms. Sandra Leung Esq.Exec. VP & Gen. Counsel2,73MN/D1961
Dr. Christopher S. BoernerExec. VP & Chief Commercialization Officer2,61MN/D1971
Mr. Rupert Vessey BCH, BM, DPHIL, M.A.Exec. VP and Pres of Research & Early Devel.3,21M1,45M1965
Mr. Greg MeyersExec. VP and Chief Digital & Technology OfficerN/DN/D1973
Mr. Timothy PowerVP & Head of Investor RelationsN/DN/DN/D
Ms. Cari GallmanSr. VP & Chief Compliance and Ethics OfficerN/DN/DN/D
Ms. Ann M. Powell JudgeExec. VP & Chief HR OfficerN/DN/D1966
Mr. Jitendra TyagiHead of US Drug Makers - IndiaN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.


Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Governance aziendale

L'ISS Governance QualityScore di Bristol-Myers Squibb Company al 1 febbraio 2023 è 3. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 4; diritti degli azionisti: 2; retribuzione: 1.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.